Investment Analysts’ Recent Ratings Changes for Oruka Therapeutics (ORKA)

Oruka Therapeutics (NASDAQ: ORKA) has recently received a number of price target changes and ratings updates:

• 3/16/2026 – Oruka Therapeutics had its price target raised by Leerink Partners from $58.00 to $86.00. They now have an “outperform” rating on the stock.
• 3/16/2026 – Oruka Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/13/2026 – Oruka Therapeutics had its price target raised by Barclays PLC from $48.00 to $50.00. They now have an “overweight” rating on the stock.
• 3/13/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $73.00 price target on the stock.
• 3/13/2026 – Oruka Therapeutics had its price target raised by Stifel Nicolaus from $47.00 to $72.00. They now have a “buy” rating on the stock.
• 3/13/2026 – Oruka Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $45.00 price target on the stock.
• 3/13/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $60.00 price target on the stock.
• 3/8/2026 – Oruka Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/28/2026 – Oruka Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Insiders Place Their Bets

In other news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares in the company, valued at $38,297,861.70. The trade was a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Joana Goncalves sold 7,641 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31. Following the transaction, the insider owned 33,377 shares in the company, valued at $1,365,453.07. The trade was a 18.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 23,765 shares of company stock valued at $849,575 in the last three months. 24.69% of the stock is owned by insiders.

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.